HighTide Therapeutics Details Board Composition and Committee Roles

An announcement from Hightide Therapeutics Inc ( (HK:2511) ) is now available.

HighTide Therapeutics Inc. announced the current composition of its board of directors, detailing the roles of executive, non-executive, and independent non-executive directors, including Chairwoman and CEO Dr. Liu Liping. The company also disclosed the structure of its three key board committees, specifying which directors serve as chairpersons or members of the audit, remuneration, and nomination committees, clarifying governance responsibilities for investors and other stakeholders.

The audit committee is chaired by independent non-executive director Mr. Chen Mingyu, with Dr. Li Jin and Mr. Hung Tak Wai as members, while the remuneration committee is led by Dr. Li Jin and the nomination committee by Dr. Liu Liping. This delineation of oversight roles underscores HighTide Therapeutics’ efforts to strengthen corporate governance, enhance transparency, and align board oversight with best practices expected in the Hong Kong capital market.

More about Hightide Therapeutics Inc

HighTide Therapeutics Inc., incorporated in the Cayman Islands and listed in Hong Kong under stock code 2511, operates in the biopharmaceutical sector. The company focuses on developing and commercializing therapeutic treatments, positioning itself as an emerging player in global healthcare and life sciences markets.

Average Trading Volume: 1,039,879

Technical Sentiment Signal: Strong Buy

Current Market Cap: HK$1.95B

For a thorough assessment of 2511 stock, go to TipRanks’ Stock Analysis page.